What can we learn from phase II adjuvant trials in melanoma?
作者信息
Keilholz U, Suciu S, Eggermont A M
出版信息
Br J Cancer. 2000 Jul;83(1):6-7. doi: 10.1054/bjoc.2000.1277.
Abstract
摘要
相似文献
1
What can we learn from phase II adjuvant trials in melanoma?
Br J Cancer. 2000 Jul;83(1):6-7. doi: 10.1054/bjoc.2000.1277.
2
The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
Br J Cancer. 2000 Jul;83(1):16-21. doi: 10.1054/bjoc.1999.1220.
3
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
J Exp Clin Cancer Res. 2000 Mar;19(1):21-34.
4
Chemotherapy and chemoimmunotherapy for metastatic malignant melanoma: review and recent advances.
Gan To Kagaku Ryoho. 2000 May;27 Suppl 2:238-47.
5
Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
Semin Oncol. 1997 Feb;24(1 Suppl 4):S44-8.
6
Biochemotherapy for melanoma: rational therapeutics in the search for weapons of melanoma destruction.
Cancer. 2004 Aug 1;101(3):435-8. doi: 10.1002/cncr.20402.
7
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Br J Cancer. 2000 Mar;82(6):1158-62. doi: 10.1054/bjoc.1999.1056.
8
Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.
Cancer Treat Rep. 1984 Nov;68(11):1403-5.
9
10
[Surgical and adjuvant drug therapy in head and neck cutaneous melanoma].
Laryngorhinootologie. 2000 Jul;79(7):428-33. doi: 10.1055/s-2000-4632.
Zotero 插件